Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Rochester, Minnesota

This page shows live ClinicalTrials.gov search results for Rochester, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
9154
Shown on this page
12
Current sort
Recently updated
Location scope
Rochester, MN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Rochester, Minnesota. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 853–864 of 9,154 matching trials in Rochester, MN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Rochester

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Recruiting Phase 3 Interventional

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Family Health Promoter - an Online Interactive Platform for Parents to Promote Healthy Habits

NCT07870304
View directory record Official record
Conditions
Health Behavior
Interventions
Not listed
Lead sponsor
Bridget Biggs
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

NCT04127578
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY3884961, Methylprednisolone, Sirolimus
Biological · Drug
Lead sponsor
Prevail Therapeutics
Industry
Eligibility
35 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
11
States / cities
Scottsdale, Arizona • Murrieta, California • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Recruiting Phase 1Phase 2 Interventional

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

NCT05636618
View directory record Official record
Conditions
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
Interventions
[203Pb]VMT-α-NET, [212Pb]VMT-α-NET
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Recruiting Phase 3 Interventional

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Completed Not applicable Interventional

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

NCT03901807
View directory record Official record
Conditions
Septic Shock, Endotoxemia
Interventions
Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
Device
Lead sponsor
Spectral Diagnostics (US) Inc.
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Recruiting Not applicable Interventional

Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass

NCT07015424
View directory record Official record
Conditions
Weight Regain, Weight Loss
Interventions
TORe with OverStitch, Intensive lifestyle modification
Device · Behavioral
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Irvine, California • Stanford, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Completed Not applicable Interventional Results available

AI-SCREENDCM Decentralized Clinical Trial - Pilot Study

NCT06609174
View directory record Official record
Conditions
Cardiomyopathy
Interventions
KardiaRx ECG Screening and AI interpretation of ECG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Recruiting No phase listed Observational

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)

NCT06297993
View directory record Official record
Conditions
PSC
Interventions
Not listed
Lead sponsor
PSC Partners Seeking a Cure
Other
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Recruiting Phase 2 Interventional

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

NCT06676579
View directory record Official record
Conditions
IgA Nephropathy (IgAN)
Interventions
Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 15, 2026, 1:02 PM EST
Recruiting Phase 2 Interventional

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

NCT06836232
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
VTX2735
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
La Jolla, California • Orange, California • Saint Augustine, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 15, 2026, 1:02 PM EST